ASSEMBLY BIOSCIENCES, INC. And Allergan Pharmaceuticals INTERNATIONAL LIMITED RESEARCH, DEVELOPMENT, COLLABORATION AND LICENSE AGREEMENT (May 8th, 2017)
[* * *] The confidential content of this Exhibit 10.1 has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Allergan Enters Into Licensing Agreement With Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development Programs -- Expands Allergan's Innovative GI Pipeline With ABI-M201 and ABI-M301, Preclinical Compounds Targeting Ulcerative Colitis and Crohn's Disease, as Well as Future Compounds for Irritable Bowel Syndrome -- (January 10th, 2017)
DUBLIN, IRELAND and INDIANAPOLIS, INDIANA (USA) - January 9, 2017 - Allergan plc (NYSE: AGN) and Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced that Allergan has entered into a research, development, collaboration and license agreement for the worldwide rights to Assembly's microbiome gastrointestinal (GI) development programs. The agreement provides Allergan with worldwide rights to preclinical compounds ABI-M201 and ABI-M301, targeting ulcerative colitis (UC) and Crohn's disease (CD), as well as two additional compounds to be identified by Assembly for Irritable Bowel Syndromes (IBS); with Diarrhea (IBS-D), with Constipation (IBS-C) or Mixed (IBS-M).
Re:General Release of Claims Agreement (December 9th, 2016)
This letter provides notice to you that effective today, November 28, 2016 (the "Separation Date") your employment with Assembly Biosciences, Inc. (the "Company") is terminating without Cause, as such term is defined in your July 11, 2014 Employment Agreement (the "Employment Agreement"). The Company thanks you for your contributions and wishes you well in your future endeavors.